Pfizer, Genzyme deal with recalls over labeling issues

Labeling problems recently tripped up two big drugmakers, Pfizer and Genzyme, which are both recalling products after they discovered missing or incorrect expiration dates. In Pfizer’s case, it is the second recall this year tied to a labeling issue.

According to the most recent FDA Enforcement report, Pfizer ($PFE) is recalling 1,316 bottles of its conjugated estrogen product, Premarin, because the labels on the 1,000-count bottles say they expire in November 2017 instead of September 2017. The recall began on September 15.

Earlier this year, Pfizer voluntarily recalled 63,636 bottles of adult Robitussin Peak Cold Cough & Chest Congestion DM Liquid in 8-oz. bottles because some bottles were mislabeled Adult Robitussin Maximum Strength Nighttime Cough DM.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

In the case of Genzyme, the biotech unit of Sanofi ($SNY), the company is recalling 9,530 vials of its stem cell transplant drug Mozobil because expiration dates may be missing from the vials. That recall, classified this week, began last month. 

Earlier this year, Genzyme voluntarily recalled more than 36,000 vials of its thyroid cancer drug Thyrogen from the U.S., Puerto Rico, Malaysia, Taiwan, Brazil and Israel. In that case, glass particles were found in some of the drugs when they were reconstituted.

- access the recalls here

Related Articles: 
Pfizer recalls mislabeled bottles of adult Robitussin 
Sanofi Genzyme recalling Thyrogen from U.S., other countries


Suggested Articles

Indoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down. 

Drugmakers have speculated about delivering temperature-sensitive vaccines and drugs using drones. Now, Merck & Co. is testing the method. 

Nexus Pharmaceuticals has moved forward the first phase of a 10-year, $250 million project to build out its sterile drug production operations.